Gene
FAT1
FAT1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (9), Actionable biomarkers (1), Trial mentions (5), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FAT1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
FAT1 has 5 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 13 of 11,460 | 0.11% |
| 2022 | 1 of 8,285 | 0.01% | 11 of 13,598 | 0.08% |
| 2021 | 0 of 8,692 | 0.00% | 20 of 15,045 | 0.13% |
| 2020 | 0 of 7,640 | 0.00% | 23 of 14,459 | 0.16% |
| 2019 | 0 of 7,300 | 0.00% | 8 of 12,159 | 0.07% |
| 2018 | 1 of 6,927 | 0.01% | 13 of 11,854 | 0.11% |
| 2017 | 0 of 6,558 | 0.00% | 14 of 11,595 | 0.12% |
Showing 10 of 37 years.
Assay-provider ledger (9)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Clinomics Inc | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 27, 2020 |
| Horizon Discovery | Reagent supplier | Clinical validationAnalytical validation | 1 | July 27, 2020 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 1 | July 27, 2020 |
| Institut Curie | Not a company | Clinical validation | 1 | March 01, 2018 |
| Agilent | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | February 20, 2015 |
Showing 5 of 9 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FAT1 oncogenic mutation | Bet Inhibitors | response-associated | head and neck squamous cell carcinoma | Cancer Genome Interpreter |
Trial mentions (5)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05495464 | Trial eligibility (AACT) |
| NCT06251310 | Trial eligibility (AACT) |
| NCT07446335 | Trial eligibility (AACT) |
| NCT05873686 | Trial eligibility (AACT) |
| NCT03254927 | Trial outcomes (AACT) |
Target-disease associations (486)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| Abnormal facial shape | phenotype | genomics england |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adenosine 5'-monophosphate measurement | measurement | GWAS credible sets |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 486 associations.
Vendor sourcing (26)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. M... | View ClinVar record SCV002058135.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV004563122.1 |
| Acerta Pharma BV (Netherlands) | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Confirmed diagnosis of mantle cell lymphoma by hematopathology. MCL should have CD20 positivity (by flow or IHC in tissue or in BM) with presence of ch... | View trial NCT05495464 |
| Acerta Pharma BV (Netherlands) | Trial collaborator | Mentioned in trial textTrial free-text mention | FAT1 | View trial NCT05495464 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.12214G>A (p.G4072R) alteration is located in exon 23 (coding exon 22) of the FAT1 gene. This alteration results from a G to A substitution at nucleotid... | View ClinVar record SCV003527087.2 |
Showing 5 of 26 sourcing records.
Trial-cited literature (158)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial. | Molecular cancer | 2025 | 8 |
| Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. | Cell | 2024 | 188 |
| Genetic modifiers of body mass index in individuals with cystic fibrosis. | American journal of human genetics | 2024 | 4 |
| YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. | Nature cancer | 2023 | 286 |
| Genomic-transcriptomic evolution in lung cancer and metastasis. | Nature | 2023 | 173 |
Showing 5 of 158 papers.
Protein variant mentions (8)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A131V | 1 | 2014 | PMID 24493827 |
| p.A4419S | 1 | 2013 | PMID 23354438 |
| p.E2496K | 1 | 2013 | PMID 23354438 |
| p.H809R | 1 | 2013 | PMID 23354438 |
| p.I2004M | 1 | 2013 | PMID 23354438 |
Showing 5 of 8 variants.
Literature-extracted relations (20)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Anhydrous glucose | Chemical | negative_correlate |
Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial. | 2020 |
| Neoplasms | Disease | associate |
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. | 2024 |
| Neoplasms, Adipose Tissue | Disease | associate |
Brown Fat-Activating Lipokine 12,13-diHOME in Human Milk Is Associated With Infant Adiposity. | 2021 |
| Diabetes Mellitus, Type 1 | Disease | associate |
Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial. | 2020 |
| Neoplasms | Disease | associate |
Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. | 2018 |
Showing 5 of 20 relation assertions.
Organizations publishing (198)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 7 | 2012 to 2024 |
| Harvard Medical School | Academic | 7 | 2014 to 2020 |
| Mass General Brigham | Hospital | 6 | 2013 to 2021 |
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2013 to 2021 |
| The University of Texas System | Academic | 5 | 2017 to 2022 |
Showing 5 of 198 organizations.
Where FAT1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
440 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.